Pierre K. Isogai

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

BACKGROUND The National Cancer Institute of Canada Clinical Trials Group CO.17 study showed that patients with advanced colorectal cancer had improved overall survival when cetuximab, an epidermal growth factor receptor-targeting antibody, was given in addition to best supportive care. We conducted a cost-effectiveness analysis using prospectively collected resource utilization and health utility data for patients in the CO.17 study who received cetuximab plus best supportive care (N = 283) or best supportive care alone (N = 274). METHODS Direct medical resource utilization data were collected, including medications, physician visits, toxicity management, blood products, emergency department visits, and hospitalizations. Mean survival times for the study arms were calculated for the entire population and for the subset of patients with wild-type KRAS tumors over an 18- to 19-month period. All costs were presented in 2007 Canadian dollars. One-way and probabilistic sensitivity analysis was used to determine the robustness of the results. Cost-effectiveness acceptability curves were determined. The 95% confidence intervals (CIs) for the incremental cost-effectiveness ratios and the incremental cost-utility ratios were estimated by use of a nonparametric bootstrapping method (with 1000 iterations). RESULTS For the entire study population, the mean improvement in overall and quality-adjusted survival with cetuximab was 0.12 years and 0.08 quality-adjusted life-years (QALYs), respectively. The incremental cost with cetuximab compared with best supportive care was

Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non–Small Cell Lung Cancer

23,969. The incremental cost-effectiveness ratio was

Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer.

199,742 per life-year gained (95% CI =

Cost-Effectiveness of Filgrastim And Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients

125,973 to

Population-based home care services in breast cancer: utilization and costs.

652,492 per life-year gained) and the incremental cost-utility ratio was

Evaluation of the Cost-Effectiveness of Electrical Stimulation Therapy for Pressure Ulcers in Spinal Cord Injury

299,613 per QALY gained (95% CI =

Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada

187,440 to

Nursing Workload Associated with Hospital Patient Care

898,201 per QALY gained). For patients with wild-type KRAS tumors, the incremental cost with cetuximab was

Prediction of Health Preference Values from CD4 Counts in Individuals with HIV

33,617 and mean gains in overall and quality-adjusted survival were 0.28 years and 0.18 QALYs, respectively. The incremental cost-effectiveness ratio was

Study Inclusion Criteria and Presentation of Results in a Meta-Analysis of Granulocyte Colony-Stimulating Factor for Prevention of Febrile Neutropenia

120,061 per life-year gained (95% CI =